Development of Xanamem, an isoform 1 specific inhibitor of 11‐βHSD, as a procognitive and disease modifying treatment for mild/moderate Alzheimer’s disease. A pharmacodynamic and biomarker driven approach

Paul Rolan, Jack A. Taylor, Jonathan R. Seckl, John Harrison, Christopher Chen, Colm Farrell, Paul Maruff, Mark Woodward, Dana HiltAlzheimer 2024 · DOI

TL;DR

This paper details the development of Xanamem, a novel drug targeting 11-βHSD1, aiming to treat Alzheimer's disease by reducing elevated cortisol levels in the brain. The study successfully established a dose-selection strategy based on brain target occupancy and demonstrated promising pro-cognitive and potential disease-modifying effects in early-stage Alzheimer's patients.

What Problem Does This Paper Address?

Developing effective treatments for Alzheimer's disease (AD) is a significant challenge, particularly for drugs targeting the central nervous system (CNS). A key hurdle is determining the optimal dose for clinical trials, especially when the drug has a novel mechanism of action. This paper addresses this by focusing on Xanamem, an inhibitor of 11-βHSD1, an enzyme involved in producing cortisol within the brain. Elevated CNS cortisol is implicated in cognitive decline, neuroinflammation, and neuronal death, all hallmarks of AD. The authors sought to establish Xanamem's clinical pharmacology, identify the right dose, and gather early evidence of its efficacy as both a cognitive enhancer and a disease modifier.

Methods

The researchers employed a multi-faceted approach to characterize Xanamem's clinical pharmacology and assess its effects. This included:

  • Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies: Data from single and multiple ascending dose (SAD/MAD) trials in healthy volunteers were analyzed to understand how the drug is absorbed, distributed, metabolized, and excreted, and what biological effects it has.
  • Population Pharmacokinetics: This statistical method was used to model drug behavior across a larger group of individuals.
  • PET Target Occupancy Study: A crucial technique involving Positron Emission Tomography (PET) scans was used to directly measure how much of the 11-βHSD1 target in the brain Xanamem occupied at various doses. This was performed in both healthy elderly participants and patients with AD.
  • Phase 2a Trial in AD Patients: This trial assessed cognitive function in patients with mild to moderate AD.
  • Phase 1b Trials: These trials in healthy older adults focused on evaluating the drug's safety profile.
  • Endocrinology and Cognitive Assessments: Blood samples were analyzed to measure hormonal changes (like ACTH and cortisol), and quantitative cognitive tests were administered to assess changes in cognitive performance.

The novel aspect here is the integration of PET-based target occupancy data with traditional PK/PD, endocrinology, and cognitive measures to guide dose selection for a CNS-targeted drug.

Datasets

The study utilized data from several clinical trials:

  • SAD and MAD dose trials: Conducted in healthy volunteers to assess PK/PD.
  • Phase 2a trial: Conducted in patients with mild/moderate Alzheimer's disease to assess cognition.
  • Multiple dose PET target occupancy study: Conducted in healthy elderly participants and Alzheimer's patients.
  • Two Phase 1b trials: Conducted in healthy older participants to assess safety.

No new benchmarks were introduced; rather, existing clinical trial methodologies and biomarker assessments were employed.

Key Insights and Ideas

  • CNS Target Occupancy is Key: The study highlights that achieving sufficient target engagement in the brain (measured by PET) is a critical determinant of drug efficacy for CNS-acting agents. This provides a more direct measure of drug action than peripheral markers alone.
  • Cortisol Modulation and Cognition: The findings suggest that inhibiting 11-βHSD1 and thereby reducing CNS cortisol can lead to improvements in cognitive functions, particularly attention and working memory. This validates the hypothesis that dysregulated cortisol plays a role in AD-related cognitive decline.
  • Potential for Disease Modification: Beyond cognitive enhancement, Xanamem showed early signs of potentially modifying the disease course, as evidenced by a slower rate of decline in a biomarker-positive AD subgroup. This suggests the drug might address underlying pathological processes.
  • Dose Selection Strategy: The research demonstrates a robust method for selecting optimal doses by correlating CNS target occupancy with pharmacodynamic and cognitive outcomes, which is invaluable for future drug development.

Key Results

  • High CNS Target Occupancy: Xanamem achieved high target occupancy in the brain across all tested doses (5-30 mg/day) as confirmed by PET scans.
  • Hormonal Effects: At doses of 5-70 mg/day, ACTH levels approximately doubled at steady-state. Plasma cortisol showed a slight reduction after the first dose but was not significantly decreased at steady-state for doses ≤ 10 mg/day, remaining within normal levels.
  • Pro-Cognitive Effects: In three trials, Xanamem demonstrated pro-cognitive effects, primarily impacting attention and working memory, at doses of 5-20 mg/day.
  • Disease Modification Signal: In patients with biomarker-positive AD (elevated plasma pTau181), Xanamem (at 10 mg/day) showed a decrease in the rate of CDR-SB worsening over 12 weeks compared to placebo, suggesting potential disease-modifying effects.

Limitations and Future Work

  • Limitations: The paper focuses on early-stage trials (Phase 1b and Phase 2a). While promising, the observed effects, particularly disease modification, require confirmation in larger, longer-term studies. The hormonal effects (doubling of ACTH) at higher doses warrant careful monitoring for potential side effects, although plasma cortisol remained within normal limits.
  • Future Work: The authors state that Xanamem is now progressing into larger Phase 2 clinical outcome trials for Major Depressive Disorder (MDD) and mild/moderate AD. These larger trials will further validate the efficacy, safety, and optimal dosing of Xanamem and provide more definitive evidence for its potential as both a procognitive and disease-modifying therapy.

Summary updated

Abstract

Abstract Background Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS‐specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem’s clinical pharmacology, including the approach to dose selection and proof‐of‐concept studies. Xanamem is an isoform 1 specific inhibitor of 11‐βHSD which acts to reduce the tissue production of cortisol. Xanamem is under clinical development as a pro‐cognitive and disease modifying drug for Alzheimer’s disease as well as other neurological and psychiatric diseases involving CNS dysregulation of cortisol. Elevation of CNS cortisol has been associated with impaired cognition, neuroinflammation, and neuronal death. Method Clinical pharmacology analyses included pharmacokinetic and pharmacodynamic data from SAD and MAD dose trials in healthy volunteers; population pharmacokinetics; cognition from patients in a phase 2a trial in Alzheimer’s disease; multiple dose PET target occupancy study to determine target inhibition in the brain in healthy elderly participants and Alzheimer’s patients; two phase 1b trials in healthy older participants that assessed safety; and pharmacodynamic endocrinology and quantitative cognitive parameters. Result Xanamem demonstrated high CNS target occupancy at all doses studied by PET (5‐30 mg/day). At doses of 5 to 70 mg/day ACTH levels approximately doubled at steady‐state. After first doses, plasma cortisol was slightly reduced but was not decreased at steady‐state in doses of ≤ 10mg/day but was within normal levels. In three trials Xanamem demonstrated pro‐cognitive effects, primarily on attention and working memory (5‐20 mg/day). Xanamem also demonstrated potentially disease modifying treatment effects in mild AD in patients with biomarker positive AD (elevation of plasma pTau181) as shown by decrease in the rate of CDR‐SB worsening over 12 weeks (10 mg/day) versus placebo. Conclusion This series of trials demonstrates that the optimal dose of Xanamem can be selected based on CNS PET occupancy data coupled with pharmacodynamic endocrinology and quantitative cognition testing. Pro‐cognitive and potentially disease modifying effects were observed at doses consistent with high CNS target occupancy. Xanamem is now in larger Phase 2 clinical outcome trials in MDD and mild/mod AD.
BibTeX
@inproceedings{rolan2024development,
  author = {Paul Rolan and Jack A. Taylor and Jonathan R. Seckl and John Harrison and Christopher Chen and Colm Farrell and Paul Maruff and Mark Woodward and Dana Hilt},
  title = {{Development of Xanamem, an isoform 1 specific inhibitor of 11‐βHSD, as a procognitive and disease modifying treatment for mild/moderate Alzheimer’s disease. A pharmacodynamic and biomarker driven approach}},
  booktitle = {Alzheimer},
  year = {2024},
  doi = {10.1002/alz.089127},
}
Figure